Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial

Background: In the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients progressing on/after platinum-based therapy. This report ev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Clement, P. M, Gauler, T, Machiels, J. P, Haddad, R. I, Fayette, J, Licitra, L. F, Tahara, M, Cohen, E. E. W, Cupissol, D, Grau, J. J, Guigay, J, Caponigro, F, de Castro, G, de Souza Viana, L, Keilholz, U, del Campo, J. M, Cong, X. J, Ehrnrooth, E, Vermorken, J. B
Format: Artikel
Sprache:eng
Schlagworte:
afatinib
HNSCC
methotrexate
older
phase III
second-line
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: In the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients progressing on/after platinum-based therapy. This report evaluates afatinib efficacy and safety in prespecified subgroups of patients aged ≥65 and
ISSN:0923-7534
DOI:10.1093/annonc/mdw151